Table 1.
Comparison of clinical characteristics between metabolic dysfunction-associated fatty liver disease with and without hepatitis B virus infection before and after propensity score matching.
| Variables | Before propensity score matching | After propensity score matching (1:1) | ||||
|---|---|---|---|---|---|---|
| MAFLD | MAFLD + HBV | P-value | MAFLD | MAFLD + HBV | P-value | |
| n (male) | 222 (161) | 179 (159) | < 0.001‡ | 83 (70) | 83 (70) | 1.000‡ |
| Age (year) | 43.50 ± 12.34 | 42.68 ± 9.91 | 0.47 | 44.35 ± 13.30 | 42.70 ± 10.31 | 0.373 |
| BMI (kg/m2) | 27.73 ± 4.85 | 26.05 ± 2.89 | 0.336 | 26.81 ± 3.59 | 27.11 ± 2.89 | 0.554 |
| SBP (mmHg) | 132.65 ± 15.15 | 131.19 ± 14.47 | 0.333 | 131.24 ± 17.10 | 132.51 ± 13.30 | 0.61 |
| DBP (mmHg) | 82.00 ± 11.45 | 81.44 ± 10.34 | 0.618 | 80.64 ± 11.19 | 81.43 ± 10.43 | 0.636 |
| SUA (μmol/L) | 391.68 ± 122.20 | 371.90 ± 86.95 | 0.077 | 381.60 ± 114.01 | 370.77 ± 92.42 | 0.515 |
| FPG (mmol/L) | 6.14 ± 1.63 | 5.82 ± 1.80 | 0.067 | 5.71 ± 0.95 | 6.04 ± 2.20 | 0.206 |
| HbA1c | 6.18 ± 1.13 | 6.25 ± 1.81 | 0.788 | 5.98 ± 1.15 | 6.57 ± 1.90 | 0.148 |
| TG (mmol/L) | 2.02 (1.38–2.84) | 1.08 (1.55–2.18) | < 0.001 | 1.73 (1.19–2.34) | 1.71 (1.20–2.59) | 0.851 |
| TC (mmol/L) | 5.05 ± 1.79 | 4.65 ± 0.89 | < 0.001 | 4.65 ± 1.02 | 4.75 ± 0.99 | 0.543 |
| LDL-c (mmol/L) | 3.17 ± 1.46 | 2.87 ± 0.72 | 0.012 | 2.87 ± 0.76 | 2.94 ± 0.80 | 0.54 |
| HDL-c (mmol/L) | 1.13 ± 0.27 | 1.10 ± 0.26 | 0.23 | 1.09 ± 0.24 | 1.09 ± 0.28 | 0.857 |
| ALT (U/L) | 41.00 (29.00–63.00) | 58.00 (36.00–86.00) | 0.002 | 56.00 (38.00–103.00) | 64.00 (37.00–98.00) | 0.801 |
| AST (U/L) | 66.00 (41.00–114.00) | 35.00 (26.00–49.00) | 0.041 | 38.00 (26.00–53.00) | 37.00 (26.00–59.00) | 0.732 |
| GGT (U/L) | 62.00 (36.00–118.00) | 40.00 (28.00–60.00) | < 0.001 | 50.00 (33.00–84.00) | 47.00 (32.00–66.00) | 0.385 |
| ALB (g/L) | 45.05 ± 4.87 | 45.02 ± 6.50 | 0.954 | 45.18 ± 4.29 | 44.81 ± 8.89 | 0.731 |
| Obesity (n, %) | 147 (66.22) | 86 (48.04) | < 0.001‡ | 58 (69.88) | 67 (80.72) | 0.105‡ |
| Hypertension (n, %) | 123 (55.41) | 58 (32.40) | < 0.001‡ | 32 (38.55) | 36 (43.37) | 0.528‡ |
| T2DM (n, %) | 46 (20.72) | 18 (10.11) | 0.004‡ | 8 (9.64) | 11 (13.25) | 0.465‡ |
| Low HDL-c (n, %) | 80 (36.04) | 36 (20.11) | < 0.001‡ | 33 (39.76) | 41 (49.40) | 0.212‡ |
| Hypertriglyceridemia (n, %) | 141 (63.51) | 76 (42.46) | < 0.001‡ | 42 (50.60) | 43 (51.80) | 0.887‡ |
| Hypercholesterolemia (n, %) | 62 (27.93) | 19 (10.61) | < 0.001‡ | 14 (16.87) | 11 (13.25) | 0.515‡ |
| Hyperuricemia (n, %) | 83 (37.39) | 42 (23.46) | 0.003‡ | 26 (31.33) | 20 (24.10) | 0.370‡ |
Data are expressed as mean ± standard deviation or median (interquartile range).
MAFLD metabolic dysfunction-associated fatty liver disease, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, SUA serum uric acid, FPG fasting plasma glucose, TG triglycerides, TC total cholesterol, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl-transferase, T2DM type 2 diabetes mellitus.